Congrès Français de Psychiatrie (CFP)
This sponsor has funded 1 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 40828 | Ongoing | Role of α1-adrenergic antagonist activity and 5-HT1A antagonism in the occurrence of ischaemic stroke and TIA within one year after a first... | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Congrès Français de Psychiatrie (CFP)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Congrès Français de Psychiatrie (CFP)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Congrès Français de Psychiatrie (CFP)
1 Study countries specified are the following:
- France